Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B

HALOZYME THERAPEUTICS, INC.

Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.
Pro forma combined 2021 revenue $627.3M, net income $286.2M; basic EPS $2.04.
Pro forma Q1 2022 revenue $158.8M, net income $36.2M; basic EPS $0.26.
Financing includes $250M term loan and $350M revolving credit facility from BofA.
Nonrecurring acquisition-related costs of $40.5M expensed in pro forma statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.